RBC Capital raised the firm’s price target on Viridian Therapeutics (VRDN) to $45 from $41 and keeps an Outperform rating on the shares following the Q3 report. Despite the government shutdown, the company submitted the applicatoin for veligrotug in late October, the analyst tells investors in a research note. The firm thinks the drug offers “meaningful differentiation” from the standard-of-care Tepezza and is highly likely to gain approval.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics price target raised to $40 from $30 at Goldman Sachs
- Viridian Therapeutics: Promising Future with Strategic Trials and Financial Stability
- Viridian Therapeutics reports Q3 EPS (34c), consensus (94c)
- Viridian Therapeutics: Promising Future with Strategic Advancements and Financial Backing
- Viridian Therapeutics: Promising Prospects with Innovative TED Treatments and Financial Stability Justify Buy Rating